Emmanuelle Clerisme-Beaty

TL;DR: The main secondary endpoints are the absolute change from baseline in King’s Brief Interstitial Lung Disease Questionnaire total score, time to first acute interstitial lung disease exacerbation or death and time to all-cause mortality over 52 weeks.

TL;DR: It is indicated that patients with fibrosing ILDs other than IPF, who are progressing despite management, have a subsequent clinical course similar to patients with untreatedIPF, with a high risk of further ILD progression and early mortality.

TL;DR: The SENSCIS trial as mentioned in this paper was a randomized, double-blind, placebo-controlled trial, in which patients with SSc-ILD were randomly assigned (1:1) to receive 150 mg of oral nintedanib twice daily or placebo for at least 52 weeks.

TL;DR: A strong predictor of COPD-related rehospitalization was prior hospitalization during the pre-index period, particularly with a primary COPD diagnosis, whilst other predictive factors related to increased COPD severity may be useful indicators for COPD -related re Hospitalization risk assessment.

TL;DR: Results from four in-depth studies show that a combined inhaler is very effective for treatment of moderate to severe chronic lung disease, which tackle airway obstruction and breathlessness, improving long-term lung function.